Viking Therapeutics Advances Oral Obesity Drug to Late-Stage Trials

Viking Therapeutics announces Phase 3 trials for its oral VK2735 obesity pill, showing up to 12.2% weight loss in early tests. Shares jump 9% as company eyes Q3 start.